RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma Ltd. announced a financially beneficial Global Termination Agreement resulting in a net balance sheet reduction of $2.3 million, strengthening their cash position and regaining control over cash collections. The agreement resolved all financial obligations from previous divestments and credit agreements, positioning the company for renewed focus on R&D and commercial growth. RedHill, which specializes in gastrointestinal and infectious diseases, is now poised to enter a new chapter of development and expansion.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
